IPO
-
-
-
-
-
-
-
Aimmune Therapeutics (AIMT) Announces Enrollment of First Patient in Phase 3 PALISADE
-
-
-
-
-
-
-
Aimmune Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
-
-
-
-
-
-
Aimmune Therapeutics (AIMT) Sees IPO Pricing of $14 - $16/Share
-
99,374 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All